Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
8
×
gene therapy
8
×
life sciences
national blog main
novartis
8
×
national
national top stories
new york top stories
biotech
boston blog main
boston top stories
clinical trials
new york blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
spinal muscular atrophy
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
zolgensma
genentech
glaxosmithkline
johnson & johnson
medical devices
abbvie
akcea therapeutics
What
bio
roundup
fda
new
therapy
cancer
days
democrats
gene
ipo
past
years
abbvie’s
age
ahead
allogene
alzheimer’s
america
approved
atrophy
august
bigger
biggest
biofourmis
biogen
biotech
bucks
busy
celebrate
chance
chemistry
cmc
come
congress
consistent
continues
controls
convoluted
corner
crispr
Language
unset
Current search:
novartis
×
" gene therapy "
×
fda
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More